Jensen, Michael Rugaard

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine

Cancer Cells and MetastasisCancer Genomics and Diagnostics

Cited by 1,393

Cyclin G Recruits PP2A to Dephosphorylate Mdm2

Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., & Prives, C. (2002) · Molecular Cell

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 215

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 87

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 85

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf −/− mouse model

Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysChromatin Remodeling and Cancer

Cited by 64